Optimizing fluoropyrimidine therapy: Real‐world impact of DPYD genotype‐based dosing on severe toxicity rates
British Journal of Clinical Pharmacology · 2026-01 · 92 (1) · 269-279
DOI: 10.1002/bcp.70266 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 30.08.2025. Verfasst von Anouk H E van Kan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, St. Antonius Hospital, Utrecht/Nieuwegein, The Netherlands. Hauptthemen laut MEDLINE: Dihydrouracil Dehydrogenase (NADP), Antimetabolites, Antineoplastic, Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Aims
Several international guidelines recommend DPYD genotype‐based dosing in patients treated with fluoropyrimidines. This study evaluates the incidences of severe fluoropyrimidine‐related toxicity between wild‐type patients and DPYD variant allele carriers in a real‐world patient cohort.
Methods
This retrospective, observational cohort study was conducted in adult patients with a first fluoropyrimidine‐based anticancer therapy. Patients were genotyped for four function variants, DPYD *2A, C.1236G>A, C.2846A>T and DPYD *13. Dosing was according to international guidelines. The primary endpoint was the incidence of severe fluoropyrimidine‐related toxicity. The secondary endpoint was to identify predictors for severe fluoropyrimidine‐related toxicity.
Results
In total, 857 patients were included of which 71 were DPYD variant allele carriers. 27% of wild‐type patients experienced severe fluoropyrimidine‐related toxicity vs . 18% of variant allele carriers ( P = 0.11). For C.1236G>A, the adjusted odds ratio (aOR) was 0.63 (95% confidence interval [CI] 0.16–2.41) following a 25% dose reduction, and 0.39 (95% CI 0.13–1.18) following a 50% dose reduction. For C.2846A>T, the aOR was 2.00 (95% CI 0.19–21.65) following a 25% dose reduction, and 1.18 (95% CI 0.22–6.53) following a 50% dose reduction. Significant independent predictors for toxicity were combination with oxaliplatin and docetaxel (aOR 10.67), oxaliplatin and irinotecan (aOR 4.66) and concurrent radiotherapy (aOR 0.18).
Conclusions
DPYD genotype‐based dosing resulted in comparable incidences of severe fluoropyrimidine‐related toxicity between wild‐type patients and DPYD variant allele carriers. The updated guideline recommendation on dosing of C.1236G>A and C.2846A>T variant carriers appears adequate from a toxicity perspective. Our findings highlight the need to perform an individual dose titration, especially in C.1236G>A variant carriers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, St. Antonius Hospital, Utrecht/Nieuwegein, The Netherlands.
- Department of Internal Medicine, St. Antonius Hospital, Utrecht, The Netherlands.
- Department of Pharmaceutics, Faculty of Science, Utrecht University, Utrecht, The Netherlands.
ORCID-Profile: Anouk H E van Kan, Ankie M Harmsze
Zitieren
APA
van Kan, A. H. E., Harmsze, A. M., Herbschleb, K., & van den Broek, M. P. H. (2026). Optimizing fluoropyrimidine therapy: Real‐world impact of DPYD genotype‐based dosing on severe toxicity rates. British Journal of Clinical Pharmacology, 92(1), 269-279. https://doi.org/10.1002/bcp.70266
Vancouver
van Kan AHE, Harmsze AM, Herbschleb K, van den Broek MPH. Optimizing fluoropyrimidine therapy: Real‐world impact of DPYD genotype‐based dosing on severe toxicity rates. British Journal of Clinical Pharmacology. 2026;92(1):269-279. doi:10.1002/bcp.70266
BibTeX
@article{vanKan2026,
author = {van Kan, Anouk H E and Harmsze, Ankie M and Herbschleb, Karin and van den Broek, Marcel P H},
title = {Optimizing fluoropyrimidine therapy: Real‐world impact of DPYD genotype‐based dosing on severe toxicity rates},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
volume = {92},
number = {1},
pages = {269--279},
doi = {10.1002/bcp.70266}
}
EUVIMED